A
ARS Pharmaceuticals, Inc. (SPRY)
NGM – Real Time Price. Currency in USD
8.54
+0.52 (6.48%)
At close: Jun 26, 2026, 4:00 PM EDT
8.80
+0.26 (3.04%)
After-hours: Jun 26, 2026, 7:44 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
8.54
+0.52 (6.48%)
At close: Jun 26, 2026, 4:00 PM EDT
8.80
+0.26 (3.04%)
After-hours: Jun 26, 2026, 7:44 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 4.94 | 6.05 | 10 | |
| Quick ratio | 4.77 | 5.63 | 10 | |
| Debt to Equity | 1.57 | 0.30 | 4.0 | |
| Debt to Assets | 0.34 | 1.04 | 6.0 | |
| Interest coverage | -24.64 | -16.91 | 1.0 | |
| Weighted average score | 6.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 1M | 30K | 89M | 84M | 99M |
| Gross Profit | 997K | -43K | 88M | 64M | 73M |
| Operating Income | -36M | -68M | -3M | -179M | -202M |
| Net Income | -35M | -54M | 8M | -171M | -198M |
| EBITDA | -35M | -67M | -3M | -178M | -201M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 108.86 | -3.48 | 5.5 |
| Next quarter | 62.46 | 38.08 | 10 |
| Current year | 77.21 | -0.57 | 5.5 |
| Next year | 83.23 | 45.37 | 10 |
| Weighted average score | 7.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -19.24 | -46.68 | -48.77 | -3.35 | 1.0 |
| Y/Y | 184.47 | -78.59 | -74.28 | -10.06 | 3.3 |
| 3y average | 98986.72 | -727.92 | -708.81 | -448.05 | 3.3 |
| 5y average | 59576.62 | -443.3 | -396.6 | -285.53 | 3.3 |
| Weighted average score | 2.7 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $96.5M significantly exceeds cash reserves ($24.3M), raising financial stability concerns
Total current assets $245.2M exceed Total current liabilities $49.6M, highlighting excellent liquidity
Debt-to-equity ratio (1.6) far exceeds the industry average, reflecting over-leverage
Interest coverage ratio (-24.6x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$44.9M limits the company's ability to reinvest or pay down debt